Chimeric antigen receptor (CAR)-T cell is a promising therapy for hematological malignancy, but further optimization is still desirable. Here the authors show that incorporating CD99, a membrane protein expressed on activated T cells, transmembrane and juxtamembrane domains into CAR design helps improve CAR-T efficacy in vitro and in vivo in mice.
- Giri Nam
- Hye Ran Yeon
- Eun Young Choi